Eur Neurol. 2001;46(2):79-82.

Mycophenolate mofetil in the therapy of severe myasthenia gravis.

Schneider C, Gold R, Reiners K, Toyka KV.

Source

Department of Neurology, University of Würzburg, Josef-Schneider-Strasse 11, D-97080 Würzburg, Germany. chris.schneider@mail.uni-wuerzburg.de

Abstract

Mycophenolate mofetil is a novel immunosuppressive drug already established in transplantation medicine. Recently, results of three open clinical trials on mycophenolate mofetil in myasthenia gravis have been reported. Mycophenolate mofetil in a dose of 1.0-2.0 g/day was given in 2 patients with severe refractory myasthenia gravis and in 1 patient with myasthenia gravis-polymyositis syndrome. Apart from dose-dependent reversible hemolytic anemia in 1 patient, no severe side effects occurred. Considerable improvement of myasthenic symptoms was seen in all patients within 3-6 months after the initiation of this therapy. Mycophenolate mofetil may be considered as a useful alternative in the treatment of severe myasthenia gravis when standard therapeutic regimens fail. It is usually well tolerated and its application is simple.

PMID:: 11528156; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience. [J Clin Neurosci. 2007]
Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
Prakash KM, Ratnagopal P, Puvanendran K, Lo YL. J Clin Neurosci. 2007 Mar; 14(3):278-81. Epub 2006 Apr 4.
Treatment of myasthenia gravis with mycophenolate mofetil: a case report. [Muscle Nerve. 2000]
Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
Meriggioli MN, Rowin J. Muscle Nerve. 2000 Aug; 23(8):1287-9.
Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. [Neurology. 2003]
Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB. Neurology. 2003 Nov 25; 61(10):1438-40.
Review Mycophenolate mofetil treatment of myasthenia gravis. [Ann Pharmacother. 2006]
Review Mycophenolate mofetil treatment of myasthenia gravis.
Cahoon WD Jr, Kockler DR. Ann Pharmacother. 2006 Feb; 40(2):295-8. Epub 2006 Jan 10.
Review Individualization of mycophenolate mofetil dose in renal transplant recipients. [Expert Opin Pharmacother. 2006]
Review Individualization of mycophenolate mofetil dose in renal transplant recipients.
van Hest RM, Hesselink DA, Vulto AG, Mathot RA, van Gelder T. Expert Opin Pharmacother. 2006 Mar; 7(4):361-76.

See reviews... See all...

Cited by 5 PubMed Central articles

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. [Ther Adv Neurol Disord. 2010]
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, et al. Ther Adv Neurol Disord. 2010 Jan; 3(1):15-28.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). [Ther Adv Neurol Disord. 2010]
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, et al. Ther Adv Neurol Disord. 2010 Jan; 3(1):3-13.
Progress in the treatment of myasthenia gravis. [Ther Adv Neurol Disord. 2008]
Progress in the treatment of myasthenia gravis.
Gold R, Hohlfeld R, Toyka KV. Ther Adv Neurol Disord. 2008 Sep; 1(2):36-51.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Eur Neurol. 2001 ;46(2):79-82.

PubMed
Liver disorder and the HFE locus.
Liver disorder and the HFE locus.
QJM. 2001 Sep ;94(9):453-6.

PubMed
Discriminative response control by psychomotor stimulants.
Discriminative response control by psychomotor stimulants.
Psychopharmacol Commun. 1976 ;2(4):331-7.

PubMed
Biological degradation of 2,4,6-trinitrotoluene.
Biological degradation of 2,4,6-trinitrotoluene.
Microbiol Mol Biol Rev. 2001 Sep ;65(3):335-52, table of contents.

PubMed
Novel cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients with prima...
Novel cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients with primary congenital glaucoma.
Invest Ophthalmol Vis Sci. 2001 Sep ;42(10):2211-6.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Mycophenolate mofetil in the therapy of severe myasthenia gravis.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 5 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information